CNBC's Meg Tirrell, has the latest details on the White House summit with medical researchers.» Read More
The first trial of an Ebola vaccine has started with the vaccination of three health care workers in Mali, researchers told NBC News.
The Ebola story has played out in the stock market recently largely on the backs of two companies: drugmakers Chimerix and Tekmira.
It's not unusual for big pharmaceutical companies to hold domains for major diseases on the Internet. But who would want to own Ebola.com?
Several drug companies are moving to test vaccines and drug treatments for Ebola, but their full effect might not be felt until the next outbreak.
Start-up Thync says it has raised $13 million to create a wearable brain device that promises to alter your state of mind, Re/code reports.
GlaxoSmithKline, which was slapped with a record fine for corruption in China, said it was looking into allegations of corruption in UAE.
Chimerix's drug brincidofovir was approved for emergency use in treating Ebola patients, and is now being used on a case in Dallas.
Chimerix said its experimental Ebola drug has been provided for potential use in patients, sending its shares sharply higher in premarket trading.
The CDC director tells CNBC Ebola's spread in West Africa raises the possibility that the U.S. will see another patient with the disease.
The U.K.'s National Institute of Health and Care Excellence recommends doctors prescribe nalmefene to mild nightly drinkers.
Encouraging employees to get a flu shot can actually save a company a lot of money, says Kaiser Permanente exec Ray Baxter.
Efforts to develop an Ebola vaccine have been in the works for some time. But experts say it's unlikely to see one available anytime soon.
Big data's potential use by humanitarian workers to stop outbreaks such as Ebola is huge, says David Richards, CEO of big data firm WANdisco.
CNBC's Dominic Chu puts together a list of companies that could be impacted by the deadly Ebola virus.
Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.
A new breast cancer drug from Roche has shown "unprecedented" benefits in extending lives in a clinical trial.
Another large shareholder of Botox-maker Allergan is expressing concern over the company's corporate governance amid its fight to hold off hostile acquirer Valeant.
Kadmon, the drug company founded by Sam Waksal of ImClone and Martha Stewart fame, is starting to look more and more like its founder's last company.
GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman.
"The stock is correct in going higher" in response to the deal, says CNBC's Jim Cramer.
Get the best of CNBC in your inbox